In a research report released today, Wedbush analyst Liana Moussatos maintained an Outperform rating on shares of Omeros Corporation (NASDAQ:OMER) with a price target …
Omeros Corporation (NASDAQ:OMER), in response to investor questions, announced that it plans to file a patent infringement lawsuit against Par Pharmaceutical, Inc. and its …
Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications …
Wedbush analyst Liana Moussatos published a new list of upcoming catalysts for a variety emerging pharmaceuticals, including XOMA Corp (NASDAQ:XOMA), Intercept Pharmaceuticals Inc …
Omeros Corporation (NASDAQ:OMER) announced that the European Commission (EC) has granted marketing authorization for Omidria (phenylephrine and ketorolac injection) 1% / 0.3% in …
In a research report issued Thursday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Omeros Corporation (NASDAQ:OMER) with a price target of $61, …
Omeros Corporation (NASDAQ:OMER) announced that the U.S.
Wedbush’s healthcare analyst Liana Moussatos weighed in today with a favorable report on Omeros Corporation (NASDAQ:OMER), reiterating an Outperform rating and a $61 price target, which represents a …
Omeros Corporation (NASDAQ:OMER) announced that Rajiv Shah, M.D.
Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan …
